Drug Trial Radar · NCT05074498
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Oct 8, 2021
Primary completion
Oct 13, 2022
Study completion Oct 13, 2022
Sponsor
- Lead sponsor
- TrueBinding, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.
Conditions
- Alzheimer's Disease
Interventions
TB006Drug
intravenous infusion
PlaceboDrug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 104
- Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)Time frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and ProteinTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea NitrogenTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1CTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and SodiumTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Clinical Chemistry Parameter: ThyrotropinTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and PlateletsTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)Time frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Hematology Parameter: HematocritTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and ReticulocytesTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)Time frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Hematology Parameter: HemoglobinTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)Time frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Urine Specific GravityTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in UrobilinogenTime frame: Baseline and up to Day 104
- Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)Time frame: Baseline and Up to Day 104
- Part 1: Change From Baseline in Respiratory RateTime frame: Baseline and Up to Day 104
- Part 1: Change From Baseline in TemperatureTime frame: Baseline and Up to Day 104
- Part 1: Change From Baseline in Heart RateTime frame: Baseline and Up to Day 104
- Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart RateTime frame: Baseline and Up to Day 104
- Part 1: Change From Baseline in ECG ParametersTime frame: Baseline and Up to Day 104
- Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 104
- Part 1: Number of Participants With Clinically Significant Physical Examination FindingsTime frame: Up to Day 104
- Part 1: Number of Participants With Clinically Significant Neurological Examination FindingsTime frame: Up to Day 104
- Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006Time frame: Day 1 and Day 29
- Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006Time frame: At Days 1, 8 and 29
- Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006Time frame: At Days 1, 8 and 29
- Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006Time frame: Day 8 and Day 29
- Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006Time frame: At Day 29
- Part 1: Total Clearance (CL) of TB006Time frame: At Day 29
- Part 1: Volume of Distribution (Vd) of TB006Time frame: At Day 29
- Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)Time frame: Day 1 (Predose), Day 8 (Predose), Day 36 and Day 104
- Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total ScoreTime frame: Baseline through Day 104
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Garden Grove, California
Clinical Trial Site
San Diego, California
Clinical Trial Site
Delray Beach, Florida
Clinical Trial Site
Lady Lake, Florida
Clinical Trial Site #1
Maitland, Florida
Clinical Trial Site
Maitland, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Stuart, Florida
Clinical Trial Site
West Palm Beach, Florida
Clinical Trial Site
Winter Park, Florida
Clinical Trial Site
Winter Park, Florida
Clinical Trial Site
Decatur, Georgia
Clinical Trial Site
Matthews, North Carolina
Clinical Trial Site
DeSoto, Texas
Clinical Trial Site
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.